Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Benzinga

Yesterday

Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.

“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.

Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.

These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.

RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.
B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.

Considering buying AXSM stock? Here’s what analysts think:

Read This Next:

Top 2 Financial Stocks That May Collapse This Month

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557315445"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557315445\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2557315445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 01:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557315445","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>, Inc</strong>. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.</p>\n<p>Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.</p>\n<p>“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.</p>\n<p>Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.</p>\n<ul>\n<li>RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.</li>\n</ul>\n<p><strong>Considering buying AXSM stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"601\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72.png 1145w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Financial Stocks That May Collapse This Month</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-08-06 01:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>, Inc</strong>. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.</p>\n<p>Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.</p>\n<p>“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.</p>\n<p>Axsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.</p>\n<ul>\n<li>RBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.</li>\n</ul>\n<p><strong>Considering buying AXSM stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"601\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/05133937/image-72.png 1145w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Financial Stocks That May Collapse This Month</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46866768/axsome-therapeutics-analysts-increase-their-forecasts-after-q2-earnings","article_id":"2557315445","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557315445","pubTimestamp":1754415651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics分析师在第二季度财报公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1},"content_text":"Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.\nAxsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.\n“Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline. We are excited by the recent approval and launch of SYMBRAVO for migraine, and are pleased with the accelerating performance of AUVELITY for depression and SUNOSI for excessive daytime sleepiness,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.\nAxsome Therapeutics shares fell 3.4% to trade at $102.89 on Tuesday.\nThese analysts made changes to their price targets on Axsome Therapeutics following earnings announcement.\n\nRBC Capital analyst Leonid Timashev maintained Axsome Therapeutics with an Outperform rating and raised the price target from $184 to $189.\nB of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $173 to $176.\n\nConsidering buying AXSM stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Financial Stocks That May Collapse This Month\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}